source
- Avere Therapeutics to go public via reverse merger, secures $320M to advance long-acting psoriasis pillAvere Therapeutics, a privately held immunology drug developer, announced a plan to become a public company through a reverse merger with NextCure. The transaction includes $320 million in new cap…
- Biogen’s experimental Alzheimer’s drug diranersen slows cognitive decline in Phase 2, matching approved therapiesBiogen reported that its experimental Alzheimer’s therapy diranersen slowed cognitive decline in a mid-stage Phase 2 study, achieving decline rates similar to those seen with drugs already on the m…